Schizophrenia/Psychosis

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

A schizophrenia research expert weighs in on the recent announcement concerning SPG302 for the treatment of individuals with schizophrenia.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Increased awareness of catatonia and its treatment among health care providers, especially in underresourced areas, is essential for improving patient outcomes.

In a survey capturing the lived experiences of individuals with schizophrenia on antipsychotic medications, 27% of participants reported that antipsychotics had done “more harm than good.”

Postpartum psychosis occurs in about 1 to 2 per thousand new mothers. In this personal story, one writer shares her experience with postpartum psychosis.

Do you want to be featured in a future Special Report? Check out our March theme!

The president of Black Psychiatrists of America shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.

Determining risks outweigh the benefits, the FDA is removing the clozapine REMS requirement.

Here are highlights from this week in Psychiatric Times, including trial updates and thoughts on the history of the antimedication movement.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis.

Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.

Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Facing limited resources, cultural barriers, and complex mental health cases, A newly qualified doctor’s year in rural South Africa offers a deep dive into psychiatry in underserved areas.

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

Although iclepertin was found to be well tolerated, the agent did not meet endpoints.

What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

Perhaps, in our modern arguments over the reality of mental illness, we are merely reinventing the wheel—or maybe, just spinning our wheels.

A recent longitudinal, retrospective study aimed to examine antipsychotic prescribing and rehospitalization rates in a forensic psychiatric sample.